Market Overview

After Data Release, Cantor Fitzgerald Doubles Bluebird Bio Price Target

Share:
After Data Release, Cantor Fitzgerald Doubles Bluebird Bio Price Target
Related BLUE
Jim Cramer Weighs In On Alibaba, Nucor, Total And More
The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results

bluebird bio Inc (NASDAQ: BLUE) reported compelling data over the weekend at the American Society of Hematology that some experts described as "unheard of."

The Analyst

Cantor Fitzgerald's Elemer Piros reiterated an Underweight on bluebird's stock with a price target boosted from $58 to $113.

The Thesis

Bluebird's data release on its Phase 1 study with the multiple myeloma treatment bb2121 provided a "strengthened profile for the therapy," as it achieved a 94 percent overall response rate, Piros said in a research report. (See Piros' track record here.) 

The data also showed an 89 percent very good partial response rate and 56 percent complete response rate in highly refractory MM patients. Cantor Fitzgerald continues to ascribe a "high" 60 percent probability of success for the program and said it could share peak sales of $2.6 billion by 2026 with its partner Celgene Corporation (NASDAQ: CELG), Piros said. 

"We believe the longer-term HbA T87Q response of 6.4g/dL and 3.0g/dL achieved in Group B patients validates the improved process' potential to address SCD," the analyst said. "While long-term questions remain, especially as they pertain to sourcing of the drug product from peripheral blood, the updated clinical data lift a key uncertainty on the ability to achieve sufficient vector copy number (VCN) in peripheral blood translating into adequate healthy hemoglobin production."

While the clinical evidence presented is encouraging, the stock's current valuation implies that SCD is "nearly de-risked (85 percent probability of success) or would generate more than the $8 billion in global revenues," Piros said. 

Price Action

Shares of bluebird soared higher by more than 25 percent ahead of Monday's market open.

Related Links:

22 Stocks Moving In Monday's Pre-Market Session

9 Notable Biotechs Presenting At This Year's ASH Meeting 

Latest Ratings for BLUE

DateFirmActionFromTo
Oct 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight
Jun 2018Evercore ISI GroupUpgradesIn-LineOutperform
May 2018PiperJaffrayAssumesOverweightOverweight

View More Analyst Ratings for BLUE
View the Latest Analyst Ratings

Posted-In: bb2121 cancer Cantor FitzgeraldAnalyst Color Health Care Price Target Reiteration Analyst Ratings Best of Benzinga

 

Related Articles (CELG + BLUE)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
AAPLWedbushInitiates Coverage On310.0
DHTJP MorganUpgrades0.0
DISBarclaysUpgrades130.0
DXCMGoldman SachsUpgrades125.0
ORLYJP MorganUpgrades398.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Benzinga's Top Upgrades, Downgrades For December 11, 2017

The Market In 5 Minutes: Bitcoin Futures Arrive, Economists On Monetary Policy, US Steel Upgrade